The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
NCT05786066
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depressive Disorder
- Major Depressive Disorder
- Bipolar Disorder
- Post Traumatic Stress Disorder
- Suicidal Ideation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Yale University
- Last updated on ClinicalTrials.gov
- May 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- VA Connecticut Healthcare System · West Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.